Development Pipeline

EA Pharma Co., Ltd. Development Pipeline as of Jan, 2020
Therapeutic Area Development Code
(Generic name)
Development Stage Indication Note
Gastrointestinal
diseases
AJM300
(carotegrast methyl)
Phase III Ulcerative colitis α4 integrin antagonist
Oral
E6007 Phase II Ulcerative colitis Integrin activation inhibitor
Oral
E6011 Phase II Crohn's disease Anti-fractalkine antibody
Injection
E3112 Phase I Liver disease Injection